Status:
TERMINATED
Effects of Fish Oil on Post Ablation Arrhythmias
Lead Sponsor:
University of Michigan
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
To determine if peri-operative treatment with omega-3 fatty acids is associated with a decrease in the incidence of early recurrences of atrial arrhythmias (within 30 days) and an improvement in proba...
Detailed Description
AF is the most prevalent arrhythmia, affecting \>2 million Americans. Antiarrhythmic drug therapy often is ineffective to eliminate recurrent episodes of AF. In recent years radiofrequency catheter ab...
Eligibility Criteria
Inclusion
- Age \> 18 years and \< 70 years old
- Left atrial size \<55 mm
Exclusion
- Inability or unwillingness to provide informed consent
- Current therapy with omega-3 fatty acids
- Current therapy with a statin
- Active liver disease
- Significant comorbidity such as end-stage renal disease or cirrhosis
- Valvular prosthesis
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00791089
Start Date
November 1 2008
End Date
October 1 2011
Last Update
September 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Cardiovascular Center
Ann Arbor, Michigan, United States, 48109